当前位置: 首页 >> 检索结果
201. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
作者: William J Sandborn.;Brian G Feagan.;Edward V Loftus.;Laurent Peyrin-Biroulet.;Gert Van Assche.;Geert D'Haens.;Stefan Schreiber.;Jean-Frederic Colombel.;James D Lewis.;Subrata Ghosh.;Alessandro Armuzzi.;Ellen Scherl.;Hans Herfarth.;Lauren Vitale.;Mohamed-Eslam F Mohamed.;Ahmed A Othman.;Qian Zhou.;Bidan Huang.;Roopal B Thakkar.;Aileen L Pangan.;Ana P Lacerda.;Julian Panes.
来源: Gastroenterology. 2020年158卷8期2123-2138.e8页
We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn's disease (CD).
202. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
作者: Eleonora Scorletti.;Paul R Afolabi.;Elizabeth A Miles.;Debbie E Smith.;Amal Almehmadi.;Albandri Alshathry.;Caroline E Childs.;Stefania Del Fabbro.;Josh Bilson.;Helen E Moyses.;Geraldine F Clough.;Jaswinder K Sethi.;Janisha Patel.;Mark Wright.;David J Breen.;Charles Peebles.;Angela Darekar.;Richard Aspinall.;Andrew J Fowell.;Joanna K Dowman.;Valerio Nobili.;Giovanni Targher.;Nathalie M Delzenne.;Laure B Bindels.;Philip C Calder.;Christopher D Byrne.
来源: Gastroenterology. 2020年158卷6期1597-1610.e7页
Dysbiosis of the intestinal microbiota has been associated with nonalcoholic fatty liver disease (NAFLD). We investigated whether administration of a synbiotic combination of probiotic and prebiotic agents affected liver fat content, biomarkers of liver fibrosis, and the composition of the fecal microbiome in patients with NAFLD.
203. Antibiotic Prophylaxis Is Not Required for Endoscopic Ultrasonography-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions, Based on a Randomized Trial.
作者: Juan Colán-Hernández.;Oriol Sendino.;Carme Loras.;Albert Pardo.;Joan B Gornals.;Mar Concepción.;Cristina Sánchez-Montes.;Marianette Murzi.;Xavier Andujar.;Julio Velasquez-Rodriguez.;Cristina Rodriguez de Miguel.;Gloria Fernández-Esparrach.;Angels Ginés.;Carlos Guarner-Argente.
来源: Gastroenterology. 2020年158卷6期1642-1649.e1页
Guidelines recommend routine antibiotic prophylaxis for patients undergoing endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, but there is conflicting evidence for its necessity. We investigated whether performing the procedure without antimicrobial prophylaxis increases the incidence of infection.
204. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial.
作者: Hua Cai.;Yue-Lan Qin.;Ze-Ya Shi.;Jin-Hui Chen.;Min-Jie Zeng.;Wei Zhou.;Ru-Qun Chen.;Zhi-Yuan Chen.
来源: BMC Gastroenterol. 2019年19卷1期219页
Alternate-day fasting (ADF) is a novel diet therapy that may achieve reduction in body weight and improvement of dyslipidaemia, but the impact of this diet on patients with non-alcoholic fatty liver disease (NAFLD) remains unknown. The aim of this study was to evaluate the effects of ADF on the body weight and lipid profile of individuals with NAFLD.
205. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
作者: Naga Chalasani.;Manal F Abdelmalek.;Guadalupe Garcia-Tsao.;Raj Vuppalanchi.;Naim Alkhouri.;Mary Rinella.;Mazen Noureddin.;Maxmillan Pyko.;Mitchell Shiffman.;Arun Sanyal.;Adam Allgood.;Harold Shlevin.;Rex Horton.;Eliezer Zomer.;William Irish.;Zachary Goodman.;Stephen A Harrison.;Peter G Traber.; .
来源: Gastroenterology. 2020年158卷5期1334-1345.e5页
Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies. We performed a phase 2b, randomized trial of the safety and efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension.
206. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
作者: William J Sandborn.;Laurent Peyrin-Biroulet.;Jinkun Zhang.;Michael Chiorean.;Séverine Vermeire.;Scott D Lee.;Tanja Kühbacher.;Bruce Yacyshyn.;Christopher H Cabell.;Snehal U Naik.;Preston Klassen.;Julián Panés.
来源: Gastroenterology. 2020年158卷3期550-561页
Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis (UC).
207. Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial.
作者: Philippe Ducrotte.;Benoit Coffin.;Bruno Bonaz.;Sébastien Fontaine.;Stanislas Bruley Des Varannes.;Frank Zerbib.;Robert Caiazzo.;Jean Charles Grimaud.;Francois Mion.;Samy Hadjadj.;Paul Elie Valensi.;Lucine Vuitton.;Guillaume Charpentier.;Alain Ropert.;Romain Altwegg.;Philippe Pouderoux.;Etienne Dorval.;Michel Dapoigny.;Henri Duboc.;Pierre Yves Benhamou.;Aurelie Schmidt.;Nathalie Donnadieu.;Guillaume Gourcerol.;Bruno Guerci.; .
来源: Gastroenterology. 2020年158卷3期506-514.e2页
There have been conflicting results from trials of gastric electrical stimulation (GES) for treatment of refractory vomiting, associated or not with gastroparesis. We performed a large, multicenter, randomized, double-blind trial with crossover to study the efficacy of GES in patients with refractory vomiting, with or without gastroparesis.
208. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial.
作者: Frances Rapport.;Clare Clement.;Anne C Seagrove.;Laith Alrubaiy.;Hayley A Hutchings.;John G Williams.
来源: BMC Gastroenterol. 2019年19卷1期166页
A nested qualitative interview study within the CONSTRUCT trial was conducted to explore experiences and perceptions of patients with acute severe ulcerative colitis following treatment with infliximab or ciclosporin, surgery, or other medication.
209. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
作者: Ikuo Hirano.;Evan S Dellon.;Jennifer D Hamilton.;Margaret H Collins.;Kathryn Peterson.;Mirna Chehade.;Alain M Schoepfer.;Ekaterina Safroneeva.;Marc E Rothenberg.;Gary W Falk.;Yehudith Assouline-Dayan.;Qiong Zhao.;Zhen Chen.;Brian N Swanson.;Gianluca Pirozzi.;Leda Mannent.;Neil M H Graham.;Bolanle Akinlade.;Neil Stahl.;George D Yancopoulos.;Allen Radin.
来源: Gastroenterology. 2020年158卷1期111-122.e10页
Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in the treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE.
210. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
作者: Selina R Cox.;James O Lindsay.;Sébastien Fromentin.;Andrew J Stagg.;Neil E McCarthy.;Nathalie Galleron.;Samar B Ibraim.;Hugo Roume.;Florence Levenez.;Nicolas Pons.;Nicolas Maziers.;Miranda C Lomer.;S Dusko Ehrlich.;Peter M Irving.;Kevin Whelan.
来源: Gastroenterology. 2020年158卷1期176-188.e7页
There is limited evidence that a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) reduces gut symptoms in quiescent inflammatory bowel disease (IBD). We performed a randomized, controlled trial to investigate the effects of a low FODMAP diet on persistent gut symptoms, the intestinal microbiome, and circulating markers of inflammation in patients with quiescent IBD.
211. Efficacy and Safety of Early vs Elective Colonoscopy for Acute Lower Gastrointestinal Bleeding.
作者: Ryota Niikura.;Naoyoshi Nagata.;Atsuo Yamada.;Tetsuro Honda.;Kenkei Hasatani.;Naoki Ishii.;Yasutoshi Shiratori.;Hisashi Doyama.;Tsutomu Nishida.;Tetsuya Sumiyoshi.;Tomoki Fujita.;Shu Kiyotoki.;Tomoyuki Yada.;Katsumi Yamamoto.;Tomohiro Shinozaki.;Munenori Takata.;Tatsuya Mikami.;Katsuhiro Mabe.;Kazuo Hara.;Mitsuhiro Fujishiro.;Kazuhiko Koike.
来源: Gastroenterology. 2020年158卷1期168-175.e6页
We performed a large, multicenter, randomized controlled trial to determine the efficacy and safety of early colonoscopy on outcomes of patients with acute lower gastrointestinal bleeding (ALGIB).
212. White-Light Endoscopy Is Adequate for Lynch Syndrome Surveillance in a Randomized and Noninferiority Study.
作者: Liseth Rivero-Sánchez.;Coral Arnau-Collell.;Jesús Herrero.;David Remedios.;Joaquín Cubiella.;Marta García-Cougil.;Victoria Alvarez.;Eduardo Albéniz.;Patricia Calvo.;Jordi Gordillo.;Ignasi Puig.;Jorge López-Vicente.;Alain Huerta.;María López-Cerón.;Inmaculada Salces.;Beatriz Peñas.;Sofía Parejo.;Enrique Rodriguez de Santiago.;Maite Herraiz.;Cristina Carretero.;Antonio Z Gimeno-Garcia.;Esteban Saperas.;Cristina Alvarez-Urturi.;Rebeca Moreira.;Cristina Rodriguez de Miguel.;Teresa Ocaña.;Leticia Moreira.;Sabela Carballal.;Ariadna Sánchez.;Gerhard Jung.;Antoni Castells.;Josep Llach.;Francesc Balaguer.;María Pellisé.; .
来源: Gastroenterology. 2020年158卷4期895-904.e1页
Dye-based pancolonic chromoendoscopy is recommended for colorectal cancer surveillance in patients with Lynch syndrome. However, there is scarce evidence to support its superiority to high-definition white-light endoscopy. We performed a prospective study assess whether in the hands of high detecting colonoscopists, high-definition, white-light endoscopy is noninferior to pancolonic chromoendoscopy for detection of adenomas in patients with Lynch syndrome.
213. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
作者: William J Sandborn.;Marc Ferrante.;Bal R Bhandari.;Elina Berliba.;Brian G Feagan.;Toshifumi Hibi.;Jay L Tuttle.;Paul Klekotka.;Stuart Friedrich.;Michael Durante.;MaryAnn Morgan-Cox.;Janelle Laskowski.;Jochen Schmitz.;Geert R D'Haens.
来源: Gastroenterology. 2020年158卷3期537-549.e10页
Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC.
214. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
作者: Zsa Zsa R M Weerts.;Ad A M Masclee.;Ben J M Witteman.;Cees H M Clemens.;Bjorn Winkens.;Jacobus R B J Brouwers.;Henderik W Frijlink.;Jean W M Muris.;Niek J De Wit.;Brigitte A B Essers.;Jan Tack.;Johanna T W Snijkers.;Andrea M H Bours.;Annieke S de Ruiter-van der Ploeg.;Daisy M A E Jonkers.;Daniel Keszthelyi.
来源: Gastroenterology. 2020年158卷1期123-136页
Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil.
215. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
作者: William J Sandborn.;Filip Baert.;Silvio Danese.;Željko Krznarić.;Taku Kobayashi.;Xiaopan Yao.;Jingjing Chen.;Maria Rosario.;Siddharth Bhatia.;Krisztina Kisfalvi.;Geert D'Haens.;Séverine Vermeire.
来源: Gastroenterology. 2020年158卷3期562-572.e12页
Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of vedolizumab for maintenance treatment. Subcutaneous vedolizumab was investigated as maintenance treatment in patients with moderately to severely active ulcerative colitis.
216. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
作者: Anna S Lok.;Mark S Sulkowski.;Jens J Kort.;Ira Willner.;K Rajender Reddy.;Mitchell L Shiffman.;Mohamed A Hassan.;Brian L Pearlman.;Federico Hinestrosa.;Ira M Jacobson.;Giuseppe Morelli.;Joy A Peter.;Monika Vainorius.;Larry C Michael.;Michael W Fried.;Gary P Wang.;Wenjing Lu.;Lois Larsen.;David R Nelson.
来源: Gastroenterology. 2019年157卷6期1506-1517.e1页
Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without ribavirin, in patients with HCV genotype 1 infection with treatment failure after sofosbuvir and an NS5A inhibitor.
217. Clip Closure After Resection of Large Colorectal Lesions With Substantial Risk of Bleeding.
作者: Eduardo Albéniz.;Marco Antonio Álvarez.;Jorge C Espinós.;Oscar Nogales.;Carlos Guarner.;Pedro Alonso.;Manuel Rodríguez-Téllez.;Alberto Herreros de Tejada.;José Santiago.;Marco Bustamante-Balén.;Joaquín Rodríguez Sánchez.;Felipe Ramos-Zabala.;Eduardo Valdivielso.;Felipe Martínez-Alcalá.;María Fraile.;Alfonso Elosua.;María Fernanda Guerra Veloz.;Berta Ibáñez Beroiz.;Ferrán Capdevila.;Mónica Enguita-Germán.
来源: Gastroenterology. 2019年157卷5期1213-1221.e4页
It is not clear whether closure of mucosal defects with clips after colonic endoscopic mucosal resection (EMR) prevents delayed bleeding, although it seems to have no protective effects when risk is low. We performed a randomized trial to evaluate the efficacy of complete clip closure of large (≥2 cm) nonpedunculated colorectal lesions after EMR in patients with an estimated average or high risk of delayed bleeding.
218. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial.
作者: Saeede Saadati.;Amir Sadeghi.;Asieh Mansour.;Zahra Yari.;Hossein Poustchi.;Mehdi Hedayati.;Behzad Hatami.;Azita Hekmatdoost.
来源: BMC Gastroenterol. 2019年19卷1期133页
The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).
219. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer.
作者: Liyana Zaharuddin.;Norfilza Mohd Mokhtar.;Khairul Najmi Muhammad Nawawi.;Raja Affendi Raja Ali.
来源: BMC Gastroenterol. 2019年19卷1期131页
Our study aimed to determine the effect of probiotic consumption containing six viable microorganisms of 30 × 1010 cfu Lactobacillus and Bifidobacteria strains for six months on clinical outcomes and inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL-17C and IL-22) in patients with colorectal cancer.
220. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
作者: Katherine Li.;Joshua R Friedman.;Daphne Chan.;Paul Pollack.;Feifei Yang.;Douglas Jacobstein.;Carrie Brodmerkel.;Christopher Gasink.;Brian G Feagan.;William J Sandborn.;Paul Rutgeerts.;Gert De Hertogh.
来源: Gastroenterology. 2019年157卷4期1019-1031.e7页
Although ustekinumab is an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic manifestations of CD are unknown.
|